Marvel Biosciences Corp (MBCOF) Ganando

Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm develops new synthetic chemical derivatives of the original approved drug for the new disease indication. The company has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The firm is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.